<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548703</url>
  </required_header>
  <id_info>
    <org_study_id>BCI-632-CL-003</org_study_id>
    <nct_id>NCT01548703</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of BCI 838 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainCells Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainCells Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and tolerability following oral administration of
      multiple doses of BCI-838 in healthy male and female subjects. The pharmacokinetic profile of
      multiple oral doses of BCI-838 in healthy male and female subjects will also be assessed. In
      addition, the pharmacodynamic effects of BCI-838 on the central nervous system using
      quantitative electroencephalogram analysis will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>14 days</time_frame>
    <description>Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632</measure>
    <time_frame>predose, at specified timepoints during the 7-day dosing period, and at Day 10 (72 hours post-dose)</time_frame>
    <description>The pharmacokinetics of BCI-838 and its metabolite BCI-632 will be completed by assessment of Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative EEG (qEEG) assessments</measure>
    <time_frame>predose, and at specified timepoints during the 7-day dosing period</time_frame>
    <description>The pharmacodynamic effects of BCI-838 on the central nervous system will be evaluated using quantitative electroencephalogram analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCI-838 Dosing Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Dosing Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Dosing Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 100 mg or matching placebo administered once daily for 7 days</description>
    <arm_group_label>BCI-838 Dosing Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.</description>
    <arm_group_label>BCI-838 Dosing Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.</description>
    <arm_group_label>BCI-838 Dosing Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female healthy volunteers, 18-55 years of age

          -  Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive

          -  Female subjects must have a negative pregnancy test at screening and admission.
             Females of childbearing potential (not at least 2 years postmenopausal or surgically
             sterile) must be using a reliable, medically acceptable form of contraception for at
             least 30 days prior to the screening visit and must agree to continue such use
             throughout the duration of the study and for 3 months after the final dose of study
             drug.

          -  Good general health as determined by medical history and physical examination with no
             clinically significant medical findings and no clinically relevant medical or surgical
             history and no acute or ongoing conditions within the past 30 days

          -  Able to participate and willing to give written informed consent and to comply with
             the study restrictions

        Exclusion Criteria:

          -  Clinically significant medical abnormality, chronic disease or history or presence of
             significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or
             neurological disorder

          -  History or current use of alcohol abuse or drug addiction

          -  Participation in a drug study within 60 days prior to drug administration.

          -  Participation in more than 3 other drug studies in the 10 months preceding the start
             of this study

          -  Donation or blood loss of more than 50 mL of blood within 60 days prior to the first
             drug administration. Donation of more than 1.5 liters of blood in the 10 months
             preceding the start of this study

          -  Illness within 5 days prior to drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah Hadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabotropic glutamate receptors 2 and 3</keyword>
  <keyword>antagonist</keyword>
  <keyword>mGluR</keyword>
  <keyword>ketamine</keyword>
  <keyword>BDNF</keyword>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Mood Disorder</keyword>
  <keyword>Phase 1 safety, tolerability and pharmacokinetics study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

